Small-molecule inhibitors of METTL3, such as STM2457, have shown promise in mouse models of acute myeloid leukemia (AML) and ALT-positive neuroblastoma, highlighting the translational potential for targeting m6A [35,77]. This evidence concerns the gene GPT and acute myeloid leukemia.